Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anthony Rees

Nurse Practitioner, Family Weirton, WV Nurse Practitioner

NPI 1104312206 CMS profile 10611300

485 Colliers Way, Weirton, WV 26062

Open in the dashboard

General payments

$7,430

481 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Rees of Weirton, WV is reported in the CMS Open Payments database as having received $7,430 across 481 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,555 95
2024 General $1,744 115
2023 General $1,237 77
2022 General $1,455 86
2021 General $1,439 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Rees
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Anthony Rees were reported at $1,555. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Anthony Rees Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,439 $124 $35–$379 $132
2022 $1,455 $141 $44–$430 $149
2023 $1,237 $154 $49–$476 $160
2024 $1,744 $165 $51–$504 $164
2025 $1,555 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,258 89 payments
  2. Novo Nordisk Inc $1,066 92 payments
  3. AstraZeneca Pharmaceuticals LP $759 36 payments
  4. Lilly USA, LLC $462 32 payments
  5. Pfizer Inc. $412 26 payments
  6. Daiichi Sankyo Inc. $319 17 payments
  7. Amgen Inc. $225 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $223 14 payments
  9. Janssen Pharmaceuticals, Inc $193 12 payments
  10. Mylan Specialty L.P. $177 10 payments
  11. Other $2,336 140 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,430 481 payments
Products named General payments · program years 2021–2025
  1. Ozempic $832 72 payments
  2. RYBELSUS $591 64 payments
  3. VRAYLAR $579 41 payments
  4. FARXIGA $479 25 payments
  5. UBRELVY $331 20 payments
  6. INJECTAFER $319 17 payments
  7. YUPELRI $291 16 payments
  8. BRILINTA $288 11 payments
  9. ELIQUIS $277 17 payments
  10. MOUNJARO $217 13 payments
  11. Other $5,055 317 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

4,957

Median for Nurse Practitioner: 389

Drug cost

$482,324

Median for Nurse Practitioner: $21,885

Branded share of claims

25.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 87 $119,639
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 84 $67,146
Eliquis Apixaban Brand 50 $37,274
Farxiga Dapagliflozin Propanediol Brand 21 $29,106
Jardiance Empagliflozin Brand 42 $28,841
Trulicity Dulaglutide Brand 29 $27,413
Nurtec Odt Rimegepant Sulfate Brand 18 $26,508
Xarelto Rivaroxaban Brand 15 $20,487
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 13 $16,135
Mounjaro Tirzepatide Brand 13 $13,591

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$16,609

Of which drugs: $480

Medicare patients

196

Average age 74

Services billed

523

105 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Depression 30%
Diabetes 28%
Ischemic heart disease 27%
COPD 23%
Chronic kidney disease 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 11 11 $397

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $222
$222 — —
YUPELRI
  • Mylan Specialty L.P. $144
$144 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $138
$138 21 —
MOUNJARO
  • Lilly USA, LLC $130
$130 13 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $79
  • Lundbeck LLC $33
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

481 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record